Literature DB >> 20622733

Clinical pathological characteristics and management of acute respiratory distress syndrome resulting from influenza A (H1N1) virus.

Samer Homsi1, Natasa Milojkovic, Yamen Homsi.   

Abstract

Young adults, especially pregnant woman and patients with pre-existing medical conditions, appear to be at risk for the development of severe acute respiratory distress syndrome (ARDS) from influenza A (H1N1) infection, leading to critical hypoxemia. This may require high ventilator settings, the use of nonconventional modes, and extracorporeal membrane oxygenation in some cases. This severe ARDS may be related to prolonged and virulent viral infection, inducing ongoing aberrant immune responses and leading to extensive lung damage. Duration of antiviral therapy, the timing of steroid introduction, and moving away from standard ventilation techniques in ARDS may be key points in disease management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622733     DOI: 10.1097/SMJ.0b013e3181e6ca0c

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Influenza induces endoplasmic reticulum stress, caspase-12-dependent apoptosis, and c-Jun N-terminal kinase-mediated transforming growth factor-β release in lung epithelial cells.

Authors:  Elle C Roberson; Jane E Tully; Amy S Guala; Jessica N Reiss; Karolyn E Godburn; Derek A Pociask; John F Alcorn; David W H Riches; Oliver Dienz; Yvonne M W Janssen-Heininger; Vikas Anathy
Journal:  Am J Respir Cell Mol Biol       Date:  2011-07-28       Impact factor: 6.914

2.  Acute Respiratory Distress Syndrome (ARDS) from Endemic Influenza A/H1N1: Prehospital Management.

Authors:  Nizama Salihefendic; Muharem Zildzic; Sead Ahmetagic
Journal:  Med Arch       Date:  2015-02-21

3.  Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: role of follow-up CT.

Authors:  G Mineo; F Ciccarese; C Modolon; M P Landini; M Valentino; M Zompatori
Journal:  Radiol Med       Date:  2011-10-21       Impact factor: 3.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.